In this episode, I sit down with the Chief Medical Officer and SVP of R&D Life Sciences at PepsiCo to discuss the company's focus on improving the nutritional profile of its portfolio for the lives they touch every day.
As a large global business, PepsiCo is acutely aware of the opportunity they
have to offer positive choices for the individuals who enjoy their products. With rising rates of chronic conditions like diabetes and obesity, the CMO explains how PepsiCo is taking a proactive approach to nutrition. PepsiCo is making a concerted effort to provide more nutritious food and beverage options that still capture the cultural and regional flavors people love.
We explore how PepsiCo is balancing consumer preferences with the need for healthier products. The CMO shares insights into PepsiCo's product innovation process and their focus on maintaining the taste and experience that individuals expect, while gradually improving the nutritional profile.
This conversation underscores the role that large corporations can play in driving improvements to their suite of products to help improve public health. Companies like PepsiCo have a tremendous opportunity - and obligation - to positively impact the lives of millions around the world.
PepsiCo is demonstrating how businesses can be a true force for good, advancing positive strategies and supporting communities globally.
About:
Dr. Tataranni is currently the Global Chief Medical Officer of PepsiCo. As Chief Medical Officer, Dr. Tataranni oversees all aspects of the company's efforts to protect its global workforce, products, and communities in the face of the COVID-19 pandemic and beyond. He also leads PepsiCo's Life Sciences strategy and the R&D Fellows Program as its Executive Sponsor. Dr. Tataranni joined PepsiCo in September, 2018 as the Senior Vice President of R&D Life Sciences, responsible for leading the development and execution of a nutrition and bio-sciences strategy in support of the company’s portfolio transformation and Pep+ agenda. Dr. Tataranni serves on the Boards of
several for-profit and non-profit organizations.
Before joining PepsiCo, Dr. Tataranni was Senior Vice President, Head of Global Medical Affairs, Diabetes & Cardiovascular Business Unit, in charge of medical strategy worldwide and operations for mature markets at Sanofi. Previous responsibilities within the group included the roles of Vice President of Global Medical Affairs, Medical Director of Europe, Vice President for the Metabolism Medical Unit in the US affiliate (2006-2008), and Medical Director for the Metabolism Franchise. Between 1999 and 2004 he was Head of the Obesity, Diabetes and Energy Metabolism Unit at the Phoenix Epidemiology and Clinical Research Branch of the National Institutes of Health in the U.S. and Director of the Clinical Research Center at the same institution from 2000 through 2004.